Global Viral Inactivation Market to reach USD 771.3 million by 2025.
Global Viral Inactivation Market valued approximately USD 319.2 million in 2016 is anticipated to grow with a healthy growth rate of more than 14.5% over the forecast period 2017-2025. Global rise in the number of chronic diseases like cancer, diabetes, autoimmune disorders, and other diseases has led to an increase in healthcare expenditure as well as increase in healthcare spending has mainly boosted the market for development of new & enhanced therapies to tackle the rise in these diseases. Increasing R&D innovation, drug discoveries, and FDA approvals leading to commercialization of new drugs has resulted in growth of the market.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors&challenges which will define the future growth of the market. Additionally, the report shall also incorporate availableopportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
§ By Method
§ Solvent Detergent Method
§ Pasteurization
§ By Product
§ Kits and Reagents
§ Services
§ Viral Inactivation Systems and Accessories
§ by Application
§ Blood & Blood Products
§ Cellular & Gene Therapy Products
§ Stem Cell Products
§ Tissue & Tissue Products
§ Vaccines and Therapeutics
§ by End User
§ Pharmaceutical and Biotechnology Companies
§ Contract Research Organizations
§ Academic Research Institutes
By Regions:
§ North America
§ U.S.
§ Canada
§ Europe
§ UK
§ Germany
§ Asia Pacific
§ China
§ India
§ Japan
§ Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2015
Base year – 2016
Forecast period – 2017 to 2025
Some of the key manufacturers involved in the market are Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGAA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.
Target Audience of the Global Viral Inactivation in Market Study:
§ Key Consulting Companies & Advisors
§ Large, medium-sized, and small enterprises
§ Venture capitalists
§ Value-Added Resellers (VARs)
§ Third-party knowledge providers
§ Investment bankers
§ Investors
